Lv3
364 积分 2026-10-02 加入
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis
2天前
已完结
Comparative efficacy of phase 2–3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis
26天前
已完结
The Framework of Precision Pharmacotherapy in Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis
1个月前
已完结
Comparative efficacy of phase 2–3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis
1个月前
已完结
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
1个月前
已完结
Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?
1个月前
已完结
Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?
1个月前
已关闭
Drug Development for MASH ‐Related Compensated Cirrhosis: Past, Present and Future
1个月前
已完结
Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
1个月前
已完结
The Framework of Precision Pharmacotherapy in Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis
1个月前
已完结